This article was originally published in Start Up
Swiss start-up GeNeuro SA aims at an MS cure. The company licensed technology from French infectious-disease specialist bioMérieux SA, whose studies showed the presence of the MS-associated retrovirus (a member of the HERV-W family) may be a major triggering and aggravating factor in MS. GeNeuro's novel approach primarily focuses on the development of therapeutic monoclonal antibodies, which will target and neutralize the pathogenic MSRV/HERV-W proteins and thereby, in theory, prevent the initiation of the inflammatory and autoimmune cascades induced by these proteins in MS.
You may also be interested in...
Servier of France will progress Swiss biotech GeNeuro’s monoclonal antibody through Phase III trials aimed at the MSRV-Env protein which, if successful, could transform how multiple sclerosis is treated.
Receptos isn't the only company in the G-coupled protein receptor oral MS drug arena, but it believes its proprietary S1P1 agonist will improve on Novartis' first-in-class S1P1 modulator Gilenya. Unlike Gilenya, which hits four of the five S1P receptor subtypes, the Receptos molecule binds selectively to S1P1 and has a predicted human half-life of approximately one day, potentially improving the safety profile and reducing complications for MS patients.
The closely watched launch of Gilenya, the first oral treatment for multiple sclerosis, may have changed the game for developing new therapies for the disease. Start-Up profiles four emerging MS drug developers: Allozyne, GeNeuro, Nuron Biotech and Receptos.